ST Pharm tops $50 million on an oligonucleotide order three times this year

At the won values Seoul Economic Daily gives for each, the three contracts come to 263.6 billion won (82.5 plus 89.8 plus 91.3) ^[1]. The paper reports cumulative orders this year of at least 260 billion won ^[7], so the three contracts alone cover the whole of that figure. Against first-half revenue of 175.4 billion won ^[12], they equal about 1.5 times six months of sales ^[3]. The report does not give delivery periods for any of them.

Profit is growing faster than sales. Working back from the reported growth rates, the first half of last year had revenue of about 120.6 billion won and operating profit of about 13.9 billion won, a margin of about 11.5% ^[4]. This year's first-half margin is 17.0% ^[5]. Of the roughly 54.8 billion won in added revenue, about 15.9 billion won reached operating profit, an incremental margin near 29% ^[6].

The link between the September contract and a single drug rests on an industry estimate ^[8] and on one analyst's reading of the supply history. "Given the existing supply record and the expanded indications, this is most likely additional order volume for Tryngolza," said Hong Ga-hye, an analyst at Daishin Securities ^[10]. "The contract also gives greater visibility on revenue growth next year," Hong said ^[11]. If the estimate holds, one drug accounts for about 36% of the dollar value of this year's three large contracts, $66.1 million of $182.4 million ^[7].

The analysts' case, as Seoul Economic Daily reports it, is that RNA drugs moving from rare diseases into chronic conditions are sending more commercial-stage orders to Korean contract manufacturers ^[1]. The report says commercial supply is more likely than clinical work to lead to repeat orders ^[5]. If that holds, the new production lines planned at the second oligonucleotide plant ^[13] fill with reorders. If the September order is instead a stock build for a newly widened label, next year could return to contracts of $50 million or less, as every order ST Pharm signed last year was ^[3]. A third outcome sits between the two: the volume holds but stays concentrated, and the company's growth follows one customer's sales.

In my view the evidence supports a change in the size and mix of ST Pharm's orders, and a weaker case that the change will last. The strongest piece is the mid-year backlog split, about $184 million of commercial work against about $46 million of clinical ^[8]. Against that, one year and three contracts, the largest tied by estimate to one drug, is a short record. The thesis fails if next year's disclosures show no order above $50 million.